CME credits: 0.25

Valid until: 14-09-2019

Claim your CME credit at https://reachmd.com/programs/cme/advances-preterm-birth-prevention-subcutaneous-intramuscular-dosing-17alpha-hydroxyprogesterone-capr/10385/

In light of the availability of a subcutaneously administered 17-OHPC, this activity will discuss strategies for providing optimal clinical management to women at risk for PTB, based on the SMFM, ACOG, and ACNM recommendations, as well as provide information surrounding the pharmacokinetic principles underlying the determination of pharmacologic bioavailability and bioequivalence, and the clinical data supporting the bioequivalence of 17-OHPC administered subcutaneously compared to the intramuscular injection. It will also define the impact of this new route of 17-OHPC administration on patient and practitioner parameters.

CME credits: 0.25

Valid until: 27-08-2020

Claim your CME credit at https://reachmd.com/cme/pulmonary-medicine/role-allergy-testing-achieve-personalized-treatment-goals-allergic-rhinitis-and-asthma/10351/

Allergic rhinitis (AR) and asthma are common allergic respiratory conditions. In fact, AR is a major factor in the development of asthma. Medical costs associated with these two conditions are high, but can be reduced considerably when following evidence-based diagnosis and treatment guidelines, which include allergy testing and avoidance of relevant allergens.

The goal of this CME activity is to help clinicians understand the rationale for allergy testing for people with AR and asthma and incorporate the results from allergy testing into a comprehensive evidence-based treatment approach.

CME credits: 0.50

Valid until: 13-08-2019

Claim your CME credit at https://reachmd.com/programs/cme/clostridium-difficile-infection-applying-new-treatment-guidelines-strategies-reduce-recurrence-rate/10339/

Clostridium difficile infection (CDI) is the leading cause of infectious nosocomial diarrhea in developed countries. Approximately 25% of patients treated for this opportunistic infection experience recurrent or recalcitrant disease, and up to 40% of those patients develop an additional recurrence. This alarming trend has sparked a much-needed update in management guidelines that aim to reduce the risk of recurrence and enhance patient care.

This activity will discuss changes to the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) guidelines, the roles of antibiotic and non-antibiotic therapies, and the importance of an interprofessional team approach to CDI.

CME credits: 0.50

Valid until: 30-11-2019

Claim your CME credit at https://reachmd.com/programs/cme/raising-expectations-rosacea-best-practices-drive-clear-results/10340/

After encountering rosacea in clinical practice on a regular basis, it can become a force of habit to focus only on the cutaneous manifestations of the disease; however, the pathophysiological changes and comorbidities that make management much more complex are often overlooked.

In this activity, Dr. J. Mark Jackson will discuss the impacts of these factors and the latest treatment strategies in alignment with current guidelines to help improve patient quality of life.

CME credits: 0.50

Valid until: 31-08-2019

Claim your CME credit at https://reachmd.com/programs/cme/raising-expectations-rosacea-best-practices-drive-clear-results/10340/

After encountering rosacea in clinical practice on a regular basis, it can become a force of habit to focus only on the cutaneous manifestations of the disease; however, the pathophysiological changes and comorbidities that make management much more complex are often overlooked.

In this activity, Dr. J. Mark Jackson will discuss the impacts of these factors and the latest treatment strategies in alignment with current guidelines to help improve patient quality of life.

CME credits: 0.75

Valid until: 02-08-2019

Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-role-for-tkis-in-rcc-highlights-from-the-18th-annual-meeting-of-the-suo/9994/

Jointly provided by and

Although renal cell carcinoma (RCC) accounts for only 2% to 3% of all adult cancers, for those who present with or progress to advanced RCC, the 5-year survival rate has never been above 10%. Several tyrosine-kinase inhibitors (TKIs), along with many other therapies, now occupy a preferred role in treatment of patients with advanced RCC, but this is a rapidly changing field. The emergence of immunotherapy for patients with RCC is reshaping the landscape of treatment options for both patients with relapse/stage IV surgically unresectable RCC and neoadjuvant therapy. Moreover, advances in the understanding of RCC biomarkers may help to identify which patients may benefit from certain therapies allowing for the possibility of more individualized treatment plans. This interactive activity features an interview with a leading expert in RCC as he discusses the current trends in clinical research in RCC treatment and how these findings are expected to impact not only guideline development but also more individualized patient care. This expert interview was recorded at and discusses some of the latest data featured at the 18th Annual Meeting of ...

CME credits: 0.25

Valid until: 31-07-2019

Claim your CME credit at https://reachmd.com/programs/cme/multiple-sclerosis-pediatric-pregnant-patients-challenges-treatment/10334/

MS is a challenging chronic disease to manage for any healthcare professional, but the most difficult cases we often face involve children and pregnant women. Up to 5% of people diagnosed with MS are under the age of 16. The peak age of diagnosis for women falls between 20 and 50 years old; however, that also happens to be the highest fertility window for these patients. Each of these populations present their own unique challenges, so on today’s program we’re going to focus on the best treatment strategies to overcome these issues for pediatric and pregnant MS patients.

Case 1:

This pediatric case involves a 7-year-old boy who develops a URI and two weeks later becomes lethargic, followed by ataxia. He presents at the ER where he was afebrile, sleepy, and unable to walk unassisted.

Case 2:

This patient is a 27-year-old, married mother of a 4-year-old boy presenting with optic neuritis, and numbness and tingling in her legs. She’s given a diagnosis of MS and placed on a first-line classic agent, interferon beta-1a. After 2 months, the patient learns she is pregnant.

CME credits: 0.25

Valid until: 31-07-2019

Claim your CME credit at https://reachmd.com/programs/cme/a-new-innovation-in-the-prevention-of-birth-prior-to-37-weeks-gestation/10319/

In light of the availability of a subcutaneously administered 17-OHPC, this activity will discuss strategies for providing optimal clinical management to women at risk for PTB, based on the SMFM, ACOG, and ACNM recommendations. In addition, it will provide information surrounding the pharmacokinetic principles underlying the determination of pharmacologic bioavailability and bioequivalence, and the clinical data supporting the bioequivalence of 17-OHPC administered subcutaneously compared to the intramuscular injection. It will also define the impact of this new route of 17-OHPC administration on patient and practitioner parameters.

Host: Amy Mackey, MD

Guest: Bahaeddine M. Sibai, MD

Guest: Judith A. Smith, PharmD, BCOP, CPHQ, FCCP, FISOPP

In light of the availability of a subcutaneously administered 17-OHPC, this activity will discuss strategies for providing optimal clinical management to women at risk for PTB, based on the SMFM, ACOG, and ACNM recommendations. In addition, it will provide information surrounding the pharmacokinetic principles underlying the determination of pharmacologic bioavailability and bioequivalence, and the clinical data supporting the bioequivalence of 17-OHPC administered subcutaneously compared to the intramuscular injection. It will also define the impact of this new route of 17-OHPC administration on patient and practitioner parameters.

CME credits: 0.25

Valid until: 30-07-2019

Claim your CME credit at https://reachmd.com/programs/cme/role-fetal-fibronectin-ffn-risk-assessment-preterm-birth-ptb/10258/

About 30% of preterm labor spontaneously resolves and 50% of patients hospitalized for preterm labor actually give birth at term. Clinicians are left with the task to effectively assess women who are at risk for prenatal delivery in order to prevent preterm labor and reduce perinatal morbidity and mortality. In this activity, clinicians will learn practical strategies combining patient history, fetal fibronectin (fFN) levels, and ultrasonography imaging results to assess patient risks for preterm delivery, in order to provide adequate counseling regarding prenatal care and lifestyle changes.

To download the algorithms mentioned in this activity, click here.1

1. McCue, B, Torbenson, VE. Fetal fibronectin: The benefits of a high negative predictive value in management of preterm labor.Contemp Ob Gyn. 2017;62(10)(suppl):1-6